A number of other equities analysts also recently commented on GXI. JPMorgan Chase & Co. set a €66.00 ($76.74) price objective on shares of Gerresheimer and gave the stock a neutral rating in a research report on Monday, October 15th. Hauck & Aufhaeuser set a €55.00 ($63.95) price objective on shares of Gerresheimer and gave the stock a neutral rating in a research report on Monday, October 15th. Berenberg Bank set a €81.00 ($94.19) price objective on shares of Gerresheimer and gave the stock a buy rating in a research report on Friday, November 23rd. Deutsche Bank set a €86.00 ($100.00) price target on shares of Gerresheimer and gave the company a buy rating in a report on Tuesday, January 15th. Finally, Credit Suisse Group set a €82.00 ($95.35) price target on shares of Gerresheimer and gave the company a buy rating in a report on Tuesday, February 5th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of €68.77 ($79.97).
Shares of Gerresheimer stock opened at €58.05 ($67.50) on Monday. Gerresheimer has a one year low of €59.97 ($69.73) and a one year high of €78.25 ($90.99).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Further Reading: Why is the price-sales ratio important?
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.